


AQLANE Medical BV Revenue
Medical Equipment Manufacturing • Oisterwijk, North Brabant, Netherlands • 1-10 Employees
AQLANE Medical BV revenue & valuation
| Annual revenue | $2,871,071 |
| Revenue per employee | $718,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Medical Equipment Manufacturing industry and current estimated revenues | $9,200,000 |
| Total funding | No funding |
Key Contact at AQLANE Medical BV
Alex Lankhorst
Director Operations & Clinical Affairs
Company overview
| Headquarters | Sprendlingenstraat 50, Oisterwijk, NB 5061 KN, NL |
| Website | |
| NAICS | 3391 |
| SIC | 384 |
| Founded | 2014 |
| Employees | 1-10 |
| Socials |
AQLANE Medical BV Email Formats
AQLANE Medical BV uses 1 email format. The most common is {first initial}.{last name} (e.g., j.doe@aqlanemedical.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}.{last name} | j.doe@aqlanemedical.com | 100% |
About AQLANE Medical BV
AQLANE Medical® is a privately owned medical device company based in Oisterwijk, The Netherlands, focused on the provision of novel bioresorbable medical solutions that are safe, effective and cost beneficial for the treatment of voiding dysfunctions. Our aim is to become the first choice in minimally invasive bioresorbable solutions for voiding dysfunctions. We operate based on our experience and expertise in the functionalization of bioresorbable polymers and gels in relation to desired device safety and efficacy performance characteristics. Bioresorbable medical polymers are very attractive because of their ease of bioresorption by hydrolysis of ester linkages and the non-toxic bioresorption products, which are resorbed through normal metabolic pathways and readily excreted. These polymers have been used for decades in various commercial FDA and CE approved medical devices. Gel components like carboxymethylcellulose are well known viscosity agents with unique elasticity and viscosity characteristics. Different polymer and viscosity formulations can be tailored to meet the required performance. The unique proprietary soft tissue augmentation technology platform is the basis of our bioresorbable medical polymer and gel formulations. Our core strategy, supported by the continuous strengthening and expansion of our organization, is leveraging Urolon®, a novel bioresorbable urethral filler, to a first-in-its-class treatment of female Stress Urinary Incontinence (SUI) and a well-accepted first-line treatment option. Urinary incontinence i.e. SUI exacts a high price, both financially and in terms of quality of life, and has a substantial impact on individual patients, health care organizations, insurers, and society as a whole. We believe Urolon® to be the ideal Urethral Filler for the safe, effective and minimally invasive treatment of SUI.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Funding Data
AQLANE Medical BV has never raised funding before.
AQLANE Medical BV Tech Stack
Discover the technologies and tools that power AQLANE Medical BV's digital infrastructure, from frameworks to analytics platforms.
Security
Caching
Form builders
JavaScript libraries
Web servers
JavaScript libraries
Programming languages
Blogs
Analytics
SEO
Tag managers
Frequently asked questions
4.8
40,000 users



